Drug Profile

Research programme: immunotherapeutics - Amunix

Alternative Names: AMX 189; AMX 268; AMX-168; AMX-182; αEpCAM-αCD3 ProTIA

Latest Information Update: 09 Feb 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amunix
Class Antineoplastics; Peptides
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

No development reported Cancer

Most Recent Events

17 Jan 2022 Amunix has been acquired by Sanofi
28 May 2021 No recent reports of development identified for preclinical development in Cancer in USA
01 Apr 2017 Preclinical trials in Cancer in USA before April 2017

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com